Increasingly accepted and accessible, the uptick of anti-wrinkle treatments continues to rise as more people explore appearance medicine options, and different demographics seek out the treatment.
Used cosmetically since the early 2000s, the age of consumers choosing a botulinum toxin A injectable has shifted as more people decide to use anti-wrinkle treatments. Appearance medicine and demand for botulinum toxin A treatments are growing more in popularity with younger demographics according to recent studies.
Also increasing, however, is the awareness of possible resistance to botulinum toxin A, and the understanding that not all forms of botulinum toxin A are the same. It’s important to be educated about the differences in treatment options available when choosing an anti-wrinkle treatment.
Therapeutic studies have shown that people may develop antibodies against botulinum toxin A over time and this may be due to increasing doses used for treatment of multiple areas, in addition to the presence of unnecessary proteins, both of which contribute to an increased level of protein used for treatment. These antibodies may increase the risk of possible resistance towards botulinum toxin A and reduce its efficacy over time.
The product you’re treated with may impact the risk of developing resistance to the treatment over time, so do your research and ask your healthcare professional for advice.
Part of the new generation of anti-wrinkle treatments is XEOMIN®. A highly purified form of botulinum toxin A without unnecessary proteins, offering another choice in the injectables market. XEOMIN® is the first and only botulinum toxin A product to contain no unnecessary complexing proteins, so there may be less chance of developing antibodies.
Its manufacturing process features additional steps that remove unnecessary complexing proteins, resulting in the purified* form of the active component of botulinum toxin A.
It works just like other botulinum toxins; injected into targeted facial muscles, XEOMIN® reduces muscle activity to soften existing facial lines. This is an option for people who want their face to look refreshed, relaxed, and even more youthful. XEOMIN® is designed to reduce forehead lines, glabella lines and crow's feet, for up-to-four months after treatment.
Manufactured in Germany by a family-owned pharmaceutical company Merz Aesthetics, XEOMIN® is available in New Zealand at clinics around the country.
For more information on XEOMIN® and how to find your local clinic visit Xeomin.co.nz
Advertisement
Advertise with NZME.*XEOMIN® contains Zero complexing proteins.
Xeomin® (Incobotulinumtoxin A) 50, 100 Units is a Prescription Medicine. Indications: In adults, for the treatment of cervical dystonia; blepharospasm; spasticity of the upper limb; upper facial lines: glabellar frown lines, lateral periorbital lines (crow's feet), horizontal forehead lines. Xeomin® has both risks and benefits, consult your doctor if Xeomin® is right for you. Further information on the risks and benefits of Xeomin® can be found in the Consumer Medicine Information (CMI) available from www.medsafe.govt.nz or by calling 0800 822 310. Use strictly as directed. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. Common side effects include: Headaches; nausea; tenderness, swelling, redness, numbness or bruising of the skin; dry eye; heavy feeling of eyelid/eyebrow/forehead; face/brow not symmetrical, dropping eyelids/eyebrows. Serious side effects are rare and include allergic reactions. Xeomin® is an unfunded medicine, prescription charge will apply. Normal doctor charges will still apply. Copyright ©2021. Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL) 58 Richard Pearse Drive, Mangere, Auckland 2022. All rights reserved. Xeomin ® and Merz Aesthetics are registered trademarks of Merz Pharma GMbH & Co. KGaA. NZ_XEO_ADV_VIVA_V1:APR21. Date of preparation: April2021. For information about how Merz handles personal data, please see Merz General Data Protection Information Notice at www.merz.com/fin TAPS1260RS
